Home LiteratureArticle Details
PMID: 15776286 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Mechanistic insight into osteoclast differentiation in osteoimmunology.

Journal of molecular medicine (Berlin, Germany) ·Vol. 83 ·No. 3 ·2005-03-00 ·Pages 170-9

Takayanagi H

Abstract

Recently a close relationship between the immune and skeletal systems or the interdisciplinary field called osteoimmunology has attracted much attention due to the observations that bone destruction is caused by an abnormal activation of the immune system in rheumatoid arthritis, and that mice lacking immunomodulatory molecules often exhibit an unexpected bone phenotype. Osteoclasts are cells of monocyte/macrophage origin that degrade the bone matrix. They are among the key players in the control of bone metabolism in health and disease. Receptor activator of NF-kappaB ligand (RANKL), a tumor necrosis factor (TNF) family cytokine, induces the differentiation of osteoclasts in the presence of macrophage-colony stimulating factor. RANKL activates TRAF6, c-Fos, and calcium signaling pathways, all of which are indispensable for the induction and activation of nuclear factor of activated T cells (NFAT) c1, the master transcription factor for osteoclastogenesis. The autoamplification of NFATc1 gene results in the efficient induction of osteoclast-specific genes. An AP-1 transcription factor complex containing c-Fos plays a crucial role in these processes, although results in conditional knockout mice show that Jun family members have a redundant role. The immunoreceptor tyrosine-based activation motif (ITAM) is an important signaling component for a number of receptors in the immune system including T-cell, B-cell, NK-cell, and Fc receptors, but its contribution to the skeletal system remains unclarified. In search for the calcium-mobilizing mechanism during osteoclastogenesis we determined that multiple immunoglobulinlike receptors associated with ITAM-harboring adaptors, Fc receptor common gamma chain (FcRgamma), and DNAX-activating protein (DAP) 12, are essential for osteoclastogenesis. In osteoclast precursor cells FcRgamma-associated receptors include osteoclast-associated receptor and paired immunoglobulinlike receptor A, while triggering receptor expressed in myeloid cells 2 and signal-regulatory protein beta1 preferentially associate with DAP12. In cooperation with RANKL these receptors activate phospholipase Cgamma and calcium signaling essential for the induction of NFATc1 through ITAM phosphorylation. Thus we have established the importance of the ITAM-mediated costimulatory signals in RANKL-induced osteoclast differentiation, which is analogous to the role of costimulatory signals in the immune system. Here we summarize recent advances in the study of signaling mechanism of osteoclast differentiation in the context of osteoimmunology.

MeSH Terms
Animals Carrier Proteins/metabolism Cell Differentiation Humans Membrane Glycoproteins/metabolism Osteoclasts/cytology,immunology,metabolism RANK Ligand Receptor Activator of Nuclear Factor-kappa B Receptors, Immunologic/immunology,metabolism Signal Transduction Transcription Factors/metabolism
Chemicals
Carrier Proteins Membrane Glycoproteins RANK Ligand Receptor Activator of Nuclear Factor-kappa B Receptors, Immunologic TNFRSF11A protein, human TNFSF11 protein, human Transcription Factors
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Takayanagi Hiroshi
Department of Cellular Physiological Chemistry, COE Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Graduate School, Tokyo Medical and Dental University, Japan. [email protected]
References (74)
74 references, click to expand
  1. Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1.
    Science. 1989 Oct 13;246(4927):249-51 PMID: 2799385
  2. Impaired differentiation of osteoclasts in TREM-2-deficient individuals.
    J Exp Med. 2003 Aug 18;198(4):645-51 PMID: 12913093
  3. Bone versus immune system.
    Nature. 2000 Nov 30;408(6812):535-6 PMID: 11117729
  4. Transcription factors of the NFAT family: regulation and function.
    Annu Rev Immunol. 1997;15:707-47 PMID: 9143705
  5. Fra-1 replaces c-Fos-dependent functions in mice.
    Genes Dev. 2000 Nov 1;14(21):2695-700 PMID: 11069886
  6. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
    Dev Cell. 2002 Dec;3(6):889-901 PMID: 12479813
  7. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos.
    J Biol Chem. 2004 Jun 18;279(25):26475-80 PMID: 15073183
  8. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.
    J Biol Chem. 1998 Oct 23;273(43):28355-9 PMID: 9774460
  9. Osteoclast differentiation and activation.
    Nature. 2003 May 15;423(6937):337-42 PMID: 12748652
  10. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice.
    Mol Cell. 2001 Oct;8(4):749-58 PMID: 11684011
  11. Identification of a putative regulator of early T cell activation genes.
    Science. 1988 Jul 8;241(4862):202-5 PMID: 3260404
  12. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects.
    J Cell Biol. 2004 Feb 16;164(4):613-23 PMID: 14769860
  13. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
    Nat Genet. 2000 Jan;24(1):45-8 PMID: 10615125
  14. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.
    J Biol Chem. 2004 Oct 29;279(44):45969-79 PMID: 15304486
  15. Murine matrix metalloproteinase 9 gene. 5'-upstream region contains cis-acting elements for expression in osteoclasts and migrating keratinocytes in transgenic mice.
    J Biol Chem. 1999 Feb 26;274(9):5588-96 PMID: 10026175
  16. AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin.
    J Biol Chem. 1996 Apr 26;271(17):9942-6 PMID: 8626631
  17. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
    Nature. 1997 Nov 13;390(6656):175-9 PMID: 9367155
  18. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
    Nature. 2000 Nov 30;408(6812):600-5 PMID: 11117749
  19. Mechanism of action of a dominant-negative mutant of c-Jun.
    Oncogene. 1994 Mar;9(3):791-9 PMID: 8108121
  20. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.
    Genes Dev. 1999 Apr 15;13(8):1015-24 PMID: 10215628
  21. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.
    J Exp Med. 2003 Aug 18;198(4):669-75 PMID: 12925681
  22. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
    Cell. 1998 Apr 17;93(2):165-76 PMID: 9568710
  23. Arming the osteoclast.
    Nat Med. 2004 May;10(5):458-60 PMID: 15122243
  24. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms.
    J Cell Sci. 2002 Nov 15;115(Pt 22):4317-25 PMID: 12376563
  25. Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
    Oncogene. 1993 Apr;8(4):877-86 PMID: 8455942
  26. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
    Genes Dev. 1998 May 1;12(9):1260-8 PMID: 9573043
  27. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase.
    Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6158-63 PMID: 15073337
  28. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
    Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 PMID: 9520411
  29. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene.
    Nature. 1990 May 31;345(6274):442-4 PMID: 2188141
  30. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway.
    Nature. 1999 Mar 18;398(6724):252-6 PMID: 10094049
  31. Genetic control of skeletal development.
    Curr Opin Genet Dev. 2001 Oct;11(5):527-32 PMID: 11532394
  32. Natural killer cells, viruses and cancer.
    Nat Rev Immunol. 2001 Oct;1(1):41-9 PMID: 11905813
  33. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    J Clin Invest. 2004 Aug;114(4):475-84 PMID: 15314684
  34. Roles of Fc receptors in autoimmunity.
    Nat Rev Immunol. 2002 Aug;2(8):580-92 PMID: 12154377
  35. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.
    J Biol Chem. 1997 Oct 3;272(40):25190-4 PMID: 9312132
  36. A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1.
    Genes Dev. 1988 Oct;2(10):1216-26 PMID: 3144478
  37. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.
    Cell. 2002 Jun 14;109(6):707-18 PMID: 12086670
  38. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.
    Nature. 2004 Apr 15;428(6984):758-63 PMID: 15085135
  39. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator.
    J Biol Chem. 2002 Oct 25;277(43):41147-56 PMID: 12171919
  40. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
    J Bone Miner Res. 2004 Jul;19(7):1059-66 PMID: 15176987
  41. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice.
    Cell. 1997 Jun 27;89(7):1021-31 PMID: 9215625
  42. Osteoprotegerin deficiency and juvenile Paget's disease.
    N Engl J Med. 2002 Jul 18;347(3):175-84 PMID: 12124406
  43. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Nature. 1999 Nov 18;402(6759):304-9 PMID: 10580503
  44. Osteoblastic cells are involved in osteoclast formation.
    Endocrinology. 1988 Nov;123(5):2600-2 PMID: 2844518
  45. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype.
    Am J Hum Genet. 2002 Sep;71(3):656-62 PMID: 12080485
  46. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice.
    J Clin Invest. 2003 Feb;111(3):323-32 PMID: 12569157
  47. Interleukin 1 and cyclic AMP induce kappa immunoglobulin light-chain expression via activation of an NF-kappa B-like DNA-binding protein.
    Mol Cell Biol. 1989 Mar;9(3):959-64 PMID: 2542770
  48. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Arthritis Rheum. 2000 Feb;43(2):259-69 PMID: 10693864
  49. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1.
    Nature. 1997 Mar 6;386(6620):81-4 PMID: 9052784
  50. RANK-L and RANK: T cells, bone loss, and mammalian evolution.
    Annu Rev Immunol. 2002;20:795-823 PMID: 11861618
  51. Reaching a genetic and molecular understanding of skeletal development.
    Dev Cell. 2002 Apr;2(4):389-406 PMID: 11970890
  52. Requirement for NF-kappaB in osteoclast and B-cell development.
    Genes Dev. 1997 Dec 15;11(24):3482-96 PMID: 9407039
  53. Genetic regulation of osteoclast development and function.
    Nat Rev Genet. 2003 Aug;4(8):638-49 PMID: 12897775
  54. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice.
    Genes Cells. 1999 Jun;4(6):353-62 PMID: 10421844
  55. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis.
    J Bone Miner Res. 2002 Jan;17(1):26-9 PMID: 11771666
  56. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation.
    Genes Dev. 2003 Aug 15;17(16):1979-91 PMID: 12923053
  57. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression.
    J Biol Chem. 2003 Jun 27;278(26):24209-16 PMID: 12695521
  58. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Endocr Rev. 1999 Jun;20(3):345-57 PMID: 10368775
  59. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation.
    Nat Genet. 2000 Feb;24(2):184-7 PMID: 10655067
  60. Medicine: interfering with bone remodelling.
    Nature. 2002 Apr 18;416(6882):686-7 PMID: 11961535
  61. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.
    Nature. 1999 Jan 28;397(6717):315-23 PMID: 9950424
  62. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.
    Science. 1994 Oct 21;266(5184):443-8 PMID: 7939685
  63. NFAT signaling: choreographing the social lives of cells.
    Cell. 2002 Apr;109 Suppl:S67-79 PMID: 11983154
  64. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts.
    Nat Med. 2002 Sep;8(9):943-9 PMID: 12161749
  65. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1.
    Science. 1987 Dec 4;238(4832):1386-92 PMID: 2825349
  66. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta.
    Nature. 2002 Apr 18;416(6882):744-9 PMID: 11961557
  67. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites.
    Science. 1988 Mar 4;239(4844):1150-3 PMID: 2964084
  68. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Annu Rev Immunol. 2001;19:163-96 PMID: 11244034
  69. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.
    Bone. 1999 Sep;25(3):261-7 PMID: 10495129
  70. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
    Endocrinology. 2004 Jun;145(6):2721-9 PMID: 14988381
  71. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis.
    EMBO J. 2001 Mar 15;20(6):1271-80 PMID: 11250893
  72. The versatility and universality of calcium signalling.
    Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21 PMID: 11413485
  73. High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype.
    J Cell Biochem. 2003 Dec 1;90(5):871-83 PMID: 14624447
  74. A novel member of the leukocyte receptor complex regulates osteoclast differentiation.
    J Exp Med. 2002 Jan 21;195(2):201-9 PMID: 11805147
Article Info
Journal
Journal of molecular medicine (Berlin, Germany)
Abbr.
J Mol Med (Berl)
ISSN
0946-2716
Published
2005-03-00
Epub
2005-00-26
Pages
170-9
Language
English
Region
Germany
NLM ID
9504370
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]